Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.2%

2 terminated out of 62 trials

Success Rate

88.9%

+2.3% vs benchmark

Late-Stage Pipeline

18%

11 trials in Phase 3/4

Results Transparency

31%

5 of 16 completed with results

Key Signals

5 with results89% success

Data Visualizations

Phase Distribution

36Total
Not Applicable (13)
Early P 1 (1)
P 1 (5)
P 2 (6)
P 3 (5)
P 4 (6)

Trial Status

Recruiting21
Completed16
Not Yet Recruiting15
Enrolling By Invitation6
Terminated2
Unknown1

Trial Success Rate

88.9%

Benchmark: 86.6%

Based on 16 completed trials

Clinical Trials (62)

Showing 20 of 20 trials
NCT07761117Phase 3Not Yet RecruitingPrimary

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

NCT07753031Not Yet Recruiting

Non-Interventional Study of Ferretab® Comp. (Ferrous Fumarate + Folic Acid Prolonged-Release Capsules) Effects in Adult Patients With Iron Deficiency Anemia and Cardiovascular Disease

NCT06678841Not ApplicableRecruitingPrimary

ELEVATE-HFpEF Clinical Study

NCT07053475Phase 4Terminated

IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches

NCT05371496Phase 4Enrolling By Invitation

Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

NCT07643818Phase 2Enrolling By InvitationPrimary

Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency

NCT07529860Not ApplicableNot Yet Recruiting

AI-based Echocardiography for Detection of Cardiac Amyloidosis

NCT07642921Not Yet RecruitingPrimary

HFpEF Phenotyping With Echo, Clinical, and Biomarkers

NCT07634640Early Phase 1RecruitingPrimary

Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction

NCT07628777Phase 1Not Yet RecruitingPrimary

Fecal Microbiota Transplantation for Elderly Patients With HFpEF: A Randomized Controlled Trial

NCT07630454Phase 4Not Yet Recruiting

Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

NCT07417215Phase 4CompletedPrimary

The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF

NCT07598760Not ApplicableNot Yet Recruiting

Clinical Feasibility of Cardiac Neuromodulation Therapy for Heart Failure With Preserved Ejection Fraction

NCT07565610Not Yet Recruiting

Changes in Intramyocardial Fat Assessed by Cardiac CT Before and After Bariatric Surgery and Their Relationship With Cardiac Diastolic Function

NCT07560436Phase 2RecruitingPrimary

Coronary Artery Stents in Heart Failure With Preserved Ejection Fraction

NCT06768437RecruitingPrimary

The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction

NCT07219511Phase 1Recruiting

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT07521293CompletedPrimary

Intracranial Pressure and a Potential Vicious Circle of Atrial Fibrillation in HFpEF

NCT07324772Not ApplicableNot Yet Recruiting

PREACTIVE: Preconditioning Exercise Intervention to Improve Symptoms and Quality of Life in Comorbid Atrial Fibrillation and HFpEF

NCT07185100RecruitingPrimary

Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

Scroll to load more

Research Network

Activity Timeline